Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients

R. G. Vincent, C. R. Mehta, R. D. Tucker, C. F. Mountain, M. Cohen, H. E. Wilson, Charles Vogel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Two hundred ten patients with advanced adenocarcinoma of the lung were entered into a two-arm randomized trail. Cytoxan + CCNU + methotrexate was compared to Adriamycin and procarbazine. The tumor response to CCM was significantly higher than the tumor response to Adriamycin and procarbazine. No significance existed between the two treatments with respect to survival. Initial performance status, weight loss prior to therapy, and response to therapy were all found to be significant prognostic factors. Median survival time relative to responders in both treatment groups was 31.7 weeks and 15.8 weeks for non-responders.

Original languageEnglish
Pages (from-to)256-260
Number of pages5
JournalCancer
Volume46
Issue number2
StatePublished - Sep 19 1980
Externally publishedYes

Fingerprint

Procarbazine
Drug Therapy
Doxorubicin
Lomustine
Survival
Therapeutics
Methotrexate
Cyclophosphamide
Weight Loss
Neoplasms
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vincent, R. G., Mehta, C. R., Tucker, R. D., Mountain, C. F., Cohen, M., Wilson, H. E., & Vogel, C. (1980). Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients. Cancer, 46(2), 256-260.

Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients. / Vincent, R. G.; Mehta, C. R.; Tucker, R. D.; Mountain, C. F.; Cohen, M.; Wilson, H. E.; Vogel, Charles.

In: Cancer, Vol. 46, No. 2, 19.09.1980, p. 256-260.

Research output: Contribution to journalArticle

Vincent, RG, Mehta, CR, Tucker, RD, Mountain, CF, Cohen, M, Wilson, HE & Vogel, C 1980, 'Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients', Cancer, vol. 46, no. 2, pp. 256-260.
Vincent RG, Mehta CR, Tucker RD, Mountain CF, Cohen M, Wilson HE et al. Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients. Cancer. 1980 Sep 19;46(2):256-260.
Vincent, R. G. ; Mehta, C. R. ; Tucker, R. D. ; Mountain, C. F. ; Cohen, M. ; Wilson, H. E. ; Vogel, Charles. / Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients. In: Cancer. 1980 ; Vol. 46, No. 2. pp. 256-260.
@article{3c43e9adcfe44565b524661a53851f41,
title = "Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients",
abstract = "Two hundred ten patients with advanced adenocarcinoma of the lung were entered into a two-arm randomized trail. Cytoxan + CCNU + methotrexate was compared to Adriamycin and procarbazine. The tumor response to CCM was significantly higher than the tumor response to Adriamycin and procarbazine. No significance existed between the two treatments with respect to survival. Initial performance status, weight loss prior to therapy, and response to therapy were all found to be significant prognostic factors. Median survival time relative to responders in both treatment groups was 31.7 weeks and 15.8 weeks for non-responders.",
author = "Vincent, {R. G.} and Mehta, {C. R.} and Tucker, {R. D.} and Mountain, {C. F.} and M. Cohen and Wilson, {H. E.} and Charles Vogel",
year = "1980",
month = "9",
day = "19",
language = "English",
volume = "46",
pages = "256--260",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients

AU - Vincent, R. G.

AU - Mehta, C. R.

AU - Tucker, R. D.

AU - Mountain, C. F.

AU - Cohen, M.

AU - Wilson, H. E.

AU - Vogel, Charles

PY - 1980/9/19

Y1 - 1980/9/19

N2 - Two hundred ten patients with advanced adenocarcinoma of the lung were entered into a two-arm randomized trail. Cytoxan + CCNU + methotrexate was compared to Adriamycin and procarbazine. The tumor response to CCM was significantly higher than the tumor response to Adriamycin and procarbazine. No significance existed between the two treatments with respect to survival. Initial performance status, weight loss prior to therapy, and response to therapy were all found to be significant prognostic factors. Median survival time relative to responders in both treatment groups was 31.7 weeks and 15.8 weeks for non-responders.

AB - Two hundred ten patients with advanced adenocarcinoma of the lung were entered into a two-arm randomized trail. Cytoxan + CCNU + methotrexate was compared to Adriamycin and procarbazine. The tumor response to CCM was significantly higher than the tumor response to Adriamycin and procarbazine. No significance existed between the two treatments with respect to survival. Initial performance status, weight loss prior to therapy, and response to therapy were all found to be significant prognostic factors. Median survival time relative to responders in both treatment groups was 31.7 weeks and 15.8 weeks for non-responders.

UR - http://www.scopus.com/inward/record.url?scp=0018828223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018828223&partnerID=8YFLogxK

M3 - Article

C2 - 6992978

AN - SCOPUS:0018828223

VL - 46

SP - 256

EP - 260

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -